These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26629731)

  • 1. Advances in the treatment of idiopathic pulmonary fibrosis.
    Sergew A; Brown KK
    Expert Opin Emerg Drugs; 2015; 20(4):537-52. PubMed ID: 26629731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targets and early stage clinical trials for pulmonary fibrosis.
    Sato S; Yanagihara T; Kolb MRJ
    Expert Opin Investig Drugs; 2019 Jan; 28(1):19-28. PubMed ID: 30513000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapeutic interventions for idiopathic pulmonary fibrosis.
    Chakraborty S; Chopra P; Ambi SV; Dastidar SG; Ray A
    Expert Opin Investig Drugs; 2014 Jul; 23(7):893-910. PubMed ID: 24766571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach?
    Mahendran S; Sethi T
    QJM; 2012 Oct; 105(10):929-34. PubMed ID: 22647761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Xaubet A; Serrano-Mollar A; Ancochea J
    Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for idiopathic pulmonary fibrosis.
    Selman M; Pardo A; Richeldi L; Cerri S
    Expert Opin Emerg Drugs; 2011 Jun; 16(2):341-62. PubMed ID: 21410428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis.
    Hara A; Sakamoto N; Ishimatsu Y; Kakugawa T; Nakashima S; Hara S; Adachi M; Fujita H; Mukae H; Kohno S
    Respir Med; 2012 Apr; 106(4):571-80. PubMed ID: 22209187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Existing and emerging treatments for idiopathic pulmonary fibrosis.
    Kolilekas L; Papiris S; Bouros D
    Expert Rev Respir Med; 2019 Mar; 13(3):229-239. PubMed ID: 30632421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
    Aryal S; Nathan SD
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options.
    Trachalaki A; Irfan M; Wells AU
    Expert Opin Pharmacother; 2021 Feb; 22(2):191-204. PubMed ID: 32993388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis.
    Fellrath JM; du Bois RM
    Clin Exp Med; 2003 Sep; 3(2):65-83. PubMed ID: 14598183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pharmacological strategies for the treatment of pulmonary fibrosis.
    Gogali A; Wells AU
    Ther Adv Respir Dis; 2010 Dec; 4(6):353-66. PubMed ID: 20864457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
    Bonella F; Stowasser S; Wollin L
    Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational drugs for idiopathic pulmonary fibrosis.
    Varone F; Montemurro G; Macagno F; Calvello M; Conte E; Intini E; Iovene B; Leone PM; Mari PV; Richeldi L
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1019-1031. PubMed ID: 28777013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials.
    Sgalla G; Lerede M; Richeldi L
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):93-101. PubMed ID: 33998354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating IPF--all or nothing? A PRO-CON debate.
    Behr J; Kolb M; Cox G
    Respirology; 2009 Nov; 14(8):1072-81. PubMed ID: 19909457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
    Spagnolo P; Maher TM; Richeldi L
    Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idiopathic pulmonary fibrosis.
    Lynch JP; Fishbein MC; Saggar R; Zisman DA; Belperio JA
    Expert Rev Respir Med; 2007 Dec; 1(3):377-89. PubMed ID: 20477177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis.
    Hosseinzadeh A; Javad-Moosavi SA; Reiter RJ; Yarahmadi R; Ghaznavi H; Mehrzadi S
    Expert Opin Ther Targets; 2018 Dec; 22(12):1049-1061. PubMed ID: 30445883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials.
    MacIsaac S; Somboonviboon D; Scallan C; Kolb M
    Expert Opin Emerg Drugs; 2024 Jun; 29(2):177-186. PubMed ID: 38588523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.